en · de · es · fr · pt
dihexa-notes.peptides6823.com › Wiki › Dihexa Chemical Identity And Origin — Background and Details

Dihexa Chemical Identity And Origin — Background and Details

By Editorial Desk · published 2025-09-19 · last reviewed 2025-10-23 · Wiki

Angiotensin IV raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-10-23 and is reviewed periodically as new material appears.

Dihexa Chemical Identity and Origin

The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.

Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.

Background and Development History

Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.

Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.

Dihexa at a glance

PropertyValueNotes
Common nameDihexaShorthand used in research literature and supplier catalogs.
CAS Registry Number1401708-83-5Identifier assigned to the synthetic peptide.
Molecular formulaC27H44N4O5Reported formula; verify with a certificate of analysis.
AppearanceWhite to off-white powderTypical form for lyophilized research peptides.
Typical storage−20 °C or below, desiccatedCommon condition for peptide stability.

Research Evidence and Regulation

Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.

Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.

Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.

Related pages on this site

Mechanism and Research Status

The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.

Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.

Dihexa Background and Classification

Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.

The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.

Reference notes

The extent to which psilocin (and by extension psilocybin) is metabolized by MAO, specifically MAO-A, is not fully clear, but has ranged from 4% to 33% in different studies based on metabolite excretion. However, circulating levels of the deaminated metabolite of psilocin are far higher than those of free unmetabolized psilocin with psilocybin administration. An early clinical study of psilocybin in combination with short-term tranylcypromine pretreatment found that tranylcypromine marginally potentiated the peripheral effects of psilocybin, including pressor effects and mydriasis, but overall did not significantly modify the psychoactive and hallucinogenic effects of the psilocybin, although some of its emotional effects were said to be reduced and some of its perceptual effects were said to be amplified. Some psychedelics are substrates of cytochrome P450 (CYP450) enzymes, for instance LSD being a substrate of CYP2D6 as well as of several other CYP450 enzymes. As such, CYP450 inhibitors may increase exposure to CYP450-substrate psychedelics such as LSD and thereby potentiate their effects as well as risks. A clinical study found that administration of LSD to people taking paroxetine, a selective serotonin reuptake inhibitor (SSRI) and strong CYP2D6 inhibitor, increased LSD exposure by about 1.5-fold. The combination was well-tolerated and did not modify the pleasant subjective effects or physiological effects of LSD, whereas negative effects of LSD, including "bad drug effect", anxiety, and nausea, were reduced.

By September 2017, the club had reached out-of-court compensation deals with all players, covering potential and actual loss of earnings and mental anguish; the sizes of the deals were confidential, but the largest payouts were understood to have gone to Jobe Watson, who was stripped of the Brownlow Medal, and Stewart Crameri, who missed the Western Bulldogs' 2016 premiership. Despite the top-up players, the weakened Essendon team was mostly uncompetitive during 2016, finishing last on the ladder with just three wins to win the wooden spoon for the first time since 1933. The club's win–loss record of 3–19 was, at the time, the second-worst in club history, and included a club-record seventeen-game losing streak (since equalled between 2025–26). Financially, the club posted a $9.8 million uninsured operating loss for the season, with roughly half of the cost in legal fees and compensation payments to the guilty players, and with reduced receipts and the payments to top-up players also having a significant effect. Ten of the twelve suspended players re-signed with Essendon for 2017; the two who departed were Michael Hibberd, who was traded to Melbourne, and Tayte Pears, who retired. There was speculation that the players could have left the club en masse, with lawyers arguing that Essendon's role in the scandal could have been considered a breach of contract, allowing the players to get out of their playing contracts and bypass other AFL player movement restrictions to qualify as delisted free agents, but no players sought this option.

In some countries, formalized training and minimum education standards exist for herbalists, although these are not necessarily uniform within or between countries. In Australia, for example, the self-regulated status of the profession (as of 2009) resulted in variable standards of training, and numerous loosely formed associations setting different educational standards. One 2009 review concluded that regulation of herbalists in Australia was needed to reduce the risk of interaction of herbal medicines with prescription drugs, to implement clinical guidelines and prescription of herbal products, and to assure self-regulation for protection of public health and safety. In the United Kingdom, the training of herbalists is done by state-funded universities offering Bachelor of Science degrees in herbal medicine. In the United States, according to the American Herbalist Guild, "there is currently no licensing or certification for herbalists in any state that precludes the rights of anyone to use, dispense, or recommend herbs." However, there are U.S. federal restrictions for marketing herbs as products intended to cure, mitigate, treat, or prevent disease.

Sources: en.wikipedia.org

Notes from published material

A study shows the clonal diversity of stem cells that produce blood cells gets drastically reduced around age 70 to a faster-growing few, substantiating a novel theory of ageing which could enable healthy aging. A study shows that blood cells' loss of the Y chromosome in a subset of cells with age, reportedly affecting at least 40% of 70 years-old men to some degree, contributes to fibrosis, heart risks, and mortality in a causal way. Researchers describe a way by which the aging of select immune system T cells can be prevented or is slowed down, with relevance to life extension and making vaccines more durable. The discovery of "super neurons" in the entorhinal cortex of people over age 80 who show exceptional episodic memory is reported. Scientists report that some apparently senescent cells – which are targeted by anti-aging senolytics – are required for regeneration, and suggest tailoring senolytics to precisely target harmful senescent cells while leaving the ones involved in regeneration intact. A study indicates that aging shifts activity toward short genes or shorter transcript length and that this can be countered by interventions. Scientists report that sphingolipids accumulate in muscle during aging whose genetic inhibition or ceramide-blockers such as myriocin could counteract, reducing associated muscle loss. By stimulating (or charging) genetically engineered roundworm mitochondria with light, researchers show that halting the decline in mitochondrial membrane potential can slow aging.

Human serum albumin is the main protein of human blood plasma. It makes up around 50% of human plasma proteins. It binds water, cations (such as Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine (T4) and pharmaceuticals (including barbiturates). Its main function is to regulate the oncotic pressure of blood. The isoelectric point of albumin is 4.7. Alpha-fetoprotein is a fetal plasma protein that binds various cations, fatty acids and bilirubin. Vitamin D-binding protein binds to vitamin D and its metabolites, as well as to fatty acids. Afamin binds vitamin E. It seems to carry lipidated Wnt proteins and Vitamin E around. Extracellular matrix protein 1 is a less canonical albumin. It regulates bone mineralization. The four canonical human albumins are arranged on chromosome 4 region 4q13.3 in a tandem manner.

These are mostly single-die LEDs used as indicators, and they come in various sizes from 1.8 mm to 10 mm, through-hole and surface mount packages. Typical current ratings range from around 1 mA to above 20 mA. LED's can be soldered to a flexible PCB strip to form LED tape popularly used for decoration. Common package shapes include round, with a domed or flat top, rectangular with a flat top (as used in bar-graph displays), and triangular or square with a flat top. The encapsulation may also be clear or tinted to improve contrast and viewing angle. Infrared devices may have a black tint to block visible light while passing infrared radiation, such as the Osram SFH 4546. 5 V and 12 V LEDs are ordinary miniature LEDs that have a series resistor for direct connection to a 5 V or 12 V supply.

Sources: en.wikipedia.org

Further detail

Nagpur–Vijayawada Expressway is part of the Nagpur-Vijayawada Economic Corridor, which will connect Nagpur-Chandrapur (part greenfield) to Mancherial-Warangal (greenfield), Warangal-Khammam (greenfield), Khammam-Vijayawada (part greenfield). The tenders were issued in November 2022, and are likely to be completed by late 2024 or mid 2025. In Feb 2026 Feb, Maharashtra government approved Rs2,353cr to acquire land for Nagpur-Chandrapur section of this expressway. Raipur–Visakhapatnam Expressway will be an alternative to the Nagpur-Vijayawada Expressway for access to various ports across the Eastern Ghats in the Bay of Bengal. The Jalna-Nanded Expressway will also provide direct connectivity between the Vijayawada–Hyderabad Expressway (at Hyderabad) and the Mumbai–Nagpur Expressway (at Jalna). The Hyderabad–Indore Expressway through Akola via Nanded–Akola–Omkareshwar–Indore, which and will further connect to the Delhi–Mumbai Expressway via the Kota–Indore Expressway (136 km).

==== Other territories ==== Darbar grossed over ₹200 crore worldwide in the 11 days after its release. The film grossed US$400,000 on its opening day in the United States. In its opening weekend, Darbar earned $1 million (₹7.09 crore) in the US. Darbar earned approximately ₹70 crore in the overseas market in the first 11 days of its release. Darbar entered the Top Five of the worldwide box office for the weekend ending 12 January 2020, following an estimated global opening of US$21.2 million.

== External links == Hepatocyte+growth+factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Hepatocyte growth factor on the Atlas of Genetics and Oncology UCSD Signaling Gateway Molecule Page on HGF Overview of all the structural information available in the PDB for UniProt: P14210 (Hepatocyte growth factor) at the PDBe-KB.

Sources: en.wikipedia.org

Frequently asked questions

What is dihexa?

Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.

Where does dihexa come from?

It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.

Is dihexa the same as angiotensin IV?

No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.

What is dihexa?

Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.

Network